Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.

Private company trial initiations stand out in the latest week’s disclosures.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.

Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.